| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 06/14/2006 | CN1259315C Antagonists of MCP-1 function and methods of use thereof |
| 06/14/2006 | CN1259307C Acylated indanyl amines and their use as pharmaceuticals |
| 06/14/2006 | CN1259100C Medicine for treating child chronic spenopathy and its preparing method |
| 06/14/2006 | CN1259071C Use of Hubei erectum in preparing anti-depression, anti-anxiety or/and brain improving medicine |
| 06/14/2006 | CN1259051C Medicines and medicinal kits |
| 06/14/2006 | CN1259049C Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| 06/14/2006 | CN1259046C Soyisoflavone soft capsule and its preparation technology |
| 06/13/2006 | US7060845 Stabilized activated derivatives of carbamic acid, their process of preparation and their use for the preparation of ureas |
| 06/13/2006 | US7060836 Lactams as tachykinin antagonists |
| 06/13/2006 | US7060827 Intermediates useful for making 2,4-pyrimidinediamine compounds |
| 06/13/2006 | US7060824 Pyrrolotriazolopyrimidinone derivatives |
| 06/13/2006 | US7060823 5-aminoalkyl-pyrazolo[4,3-d]pyrimidines with a phosphodiesterase v-inhibiting effect |
| 06/13/2006 | US7060821 Osteoclast differentiation inhibitors |
| 06/13/2006 | US7060802 Monoclonal antibody hybridomas ; detecting cancer |
| 06/13/2006 | US7060800 Polypeptides for use in the treatment and diagnosis of crohn's disease |
| 06/13/2006 | US7060732 Antiacne; skin disorders; packaged separately |
| 06/13/2006 | US7060731 Such as meglumine, 3-methylamino-1,2 propandiol or 2-(methylamino)-ethanol as complement inhibitors, to combact activation of the kinin/kallikrein system or as an anticoagulant |
| 06/13/2006 | US7060722 Proline derivatives and use thereof as drugs |
| 06/13/2006 | US7060721 Phosphodiesterase inhibitor; antidiabetic agents; atherosclerosis; cardiovascular disorders; polyctstic ovary syndrome; hypotensive agents; hyperglycemic agents |
| 06/13/2006 | US7060720 Compounds useful for treating or preventing IMPDH associated disorders, such as transplant rejection and autoimmune diseases and inhibitors of inosine-5'-monophosphate dehydrogenase). The compounds and pharmaceutical compositions |
| 06/13/2006 | US7060716 Compound containing two triple bonds |
| 06/13/2006 | US7060707 Isoquinoline derivatives |
| 06/13/2006 | US7060705 2-(saturated N-heterocycylalkyl) quinazolinone compounds, e.g., 3-benzyl-2-[1-(4-methylpiperazin-1-yl)propyl]quinazolin-4(3H)-one, used to treat cancer, especially histiocytic lymphoma, lung adenocarcinoma, small cell lung cancer, pancreatic cancer, glioblastoma and breast carcinoma |
| 06/13/2006 | US7060703 Indolinone derivatives |
| 06/13/2006 | US7060701 piperidines or piperazines 1-linked to a 1-(1-carbonylpiperidin-4-yl)piperidinyl- group through an optionally substituted methyl group; treating Human Immuno-deficiency Virus, solid organ transplant rejection, arthritis, rheumatoid arthritis, and multiple sclerosis |
| 06/13/2006 | US7060700 Amide derivatives useful as inhibitors of the production of cytokines |
| 06/13/2006 | US7060699 Aryl and heteroaryl diazabicycloalkanes, their preparation and use |
| 06/13/2006 | US7060685 Benzylaminosulfonic Acid or portion or analogue linked to a carbohydrate or glycomimetic for modulating processes mediated by selectin binding such as autoimmune and inflammatory diseases, shock and reperfusion injuries |
| 06/13/2006 | US7060683 for treatment of neurodegeneration, stroke, Alzheimer's, amyotrophy, motor neuron damage, acute central nervous system injury, muscular dystrophy, bone resorption, platelet aggregation, cataracts and inflammation |
| 06/13/2006 | US7060681 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |
| 06/13/2006 | US7060679 having a building unit containing one nitrogen atom of the peptide backbone connected to a bridging group comprising an amide, thioether, thioester, or disulfide; used to treat cancers, diabetes, diabetic-associated complications, endocrine disorders, gastrointestinal disorders, and pancreatitis |
| 06/13/2006 | US7060504 High mobility group proteins; diagnostic monitoring the severity or potential lethality of sepsis or septic shock, measuring the serum protein concentration of patient, treating weight loss or obesity |
| 06/13/2006 | US7060500 Single-stranded oligodeoxynucleotide mutational vectors |
| 06/13/2006 | US7060498 Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers |
| 06/13/2006 | US7060466 Methods of producing hyaluronic acid using a recombinant hyaluronan synthase gene |
| 06/13/2006 | US7060305 extracts contain higher concentration of isoflavones; used to treat erectile dysfunction or malfunction |
| 06/13/2006 | US7060290 Phosphocholine linked prodrug derivatives |
| 06/13/2006 | US7060278 Bv8 nucleic acids and polypeptides with mitogenic activity |
| 06/13/2006 | US7060261 Nucleotide sequences coding polypeptide for us ein the treatment of immunological disorders |
| 06/13/2006 | US7060259 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol) |
| 06/13/2006 | US7060254 Aerosol; heating thin film on solid support; vaporization with air flow |
| 06/13/2006 | CA2387997C Process for preparing oxazolines from tetrahydrofurans |
| 06/13/2006 | CA2366623C Resorcinol composition |
| 06/13/2006 | CA2362903C Novel sulfofucosylacylglycerol derivatives and use thereof as medicaments |
| 06/13/2006 | CA2237194C Furan- and thiophenecarbothioamide derivatives, their preparation and their use as inhibitors of the replication of hiv-1 and hiv-1 mutants |
| 06/08/2006 | WO2006059801A1 7-membered ring compound, process for producing the same, and medicinal use thereof |
| 06/08/2006 | WO2006059785A1 Development of bioactive agent using dendritic cell differentiation-inducing factor |
| 06/08/2006 | WO2006059778A1 Substituted pyridone derivative |
| 06/08/2006 | WO2006059777A1 Remedy for alzheimer’s disease |
| 06/08/2006 | WO2006059744A1 ACTIVATOR OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR δ |
| 06/08/2006 | WO2006059637A1 Agent for diagnosing, preventing and treating adhesion with the use of ccr8 inhibitor |
| 06/08/2006 | WO2006059507A1 11β-HSD1 ANTISENSE COMPOUND |
| 06/08/2006 | WO2006016115A3 Method and means for enhanced pulmonary drug delivery |
| 06/08/2006 | WO2006000464A3 Method for discovering pain-relevant substances using pain-relevant proteins |
| 06/08/2006 | WO2005092069A3 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof |
| 06/08/2006 | WO2003077857A3 N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors |
| 06/08/2006 | US20060123498 Paks as modifiers of the chk pathway and methods of use |
| 06/08/2006 | US20060122411 Chloride channel opener |
| 06/08/2006 | US20060122392 Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient |
| 06/08/2006 | US20060122390 Boronic ester and acid compounds, synthesis and uses |
| 06/08/2006 | US20060122280 Muscarinic agonists |
| 06/08/2006 | US20060122275 Agentfor reducing side effects of diclofenac |
| 06/08/2006 | US20060122270 Use of medium chain triglycerides for the treatment and prevention of Alzheimer's disease and other diseases resulting from reduced neuronal metabolism |
| 06/08/2006 | US20060122268 Such as N1-(1-cyanocyclopropyl)-4-fluoro-N2-((1S)-2,2,2-trifluoro-1-(4' -(methylsulfonyl)-1,1'-biphenyl-4-yl) ethyl)-L-leucinamide; for treating osteoporosis and other bone loss disorders |
| 06/08/2006 | US20060122264 Stem cell invasion inhibitor |
| 06/08/2006 | US20060122259 Immobilization of taxane; anticancer, antitumor agents |
| 06/08/2006 | US20060122249 Condensed heterocyclic pyrazole derivatives as kinase inhibitors |
| 06/08/2006 | US20060122245 Novel inhibitors of IMPDH enzyme |
| 06/08/2006 | US20060122242 2-Aryloxy-2-arylalkanoic acids for diabetes and lipid disorders |
| 06/08/2006 | US20060122239 Lipid diseases; metabolism diosrders; antiproliferative agents |
| 06/08/2006 | US20060122234 Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors |
| 06/08/2006 | US20060122221 N-[4-methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)phenyl]-2-pyrrolidin-1-ylisonicotinamide; rheumatoid arthritis |
| 06/08/2006 | US20060122207 Imidazol derivatives as Raf kinase inhibitors |
| 06/08/2006 | US20060122191 N-(indolethyl-)cycloamine compounds |
| 06/08/2006 | US20060122183 Synergistic; side effect reduction; melanomas; toxicity; 2,5-Dimethoxythiobenzoic Acid N-methylhydrazine; anticancer |
| 06/08/2006 | US20060122181 Heteroaromatic pentacyclic compound and medicinal use thereof |
| 06/08/2006 | US20060122176 such as 5-(1,3-benzodioxol-5-ylmethylene)-1,3-thiazolidine-2,4-dione, used for the treatment and/or prophylaxis of autoimmune, cardiovascular or neurodegenerative disorders, inflammatory or kidney diseases, bacterial or viral infections, platelet aggregation, cancer, transplant rejection or lung injuries |
| 06/08/2006 | US20060122170 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivative or salt thereof |
| 06/08/2006 | US20060122169 Succinoylamino benzodiazepines as inhibitors of Abeta protein production |
| 06/08/2006 | US20060122111 Regeneration and neogenesis of retinal visual cell otx2 gene |
| 06/08/2006 | US20060122105 Method of improing the growth performance of an animal |
| 06/08/2006 | US20060122101 Drug for preventing, regulating or treating adhesion |
| 06/08/2006 | US20060121538 Peptides having affinity for the gp120 viral protein and use thereof |
| 06/08/2006 | US20060121529 CpG receptor (CpG-R) and methods relating thereto |
| 06/08/2006 | US20060121526 Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression |
| 06/08/2006 | US20060121514 Prostacyclin-stimulating Factor-2 |
| 06/08/2006 | US20060121465 Sgk and nedd used as diagnostic and therapeutic targets |
| 06/08/2006 | US20060121180 Using electrochemical solution containing metal compound and bioactive materials; contacting substrate |
| 06/08/2006 | US20060121132 TNF-alpha production inhibitor comprising kavalactone as an active ingredient |
| 06/08/2006 | US20060121107 Agent improving proton-driven transporter-mediated absorption in digestive tract and process for producing the same |
| 06/08/2006 | US20060121094 Preparation comprising 1,3 and/or 1,6 beta glucans for the treatment of infections and inflammations in animals |
| 06/08/2006 | US20060121088 delivering to an external portion of the body passageway a therapeutic agent such as an antiangiogenic factor from a thread; treating stenosis or restenosis for example |
| 06/08/2006 | US20060121079 Delivering a dose of gold, silver or an alloy of particles having a cross-sectional diameter of >20 mu m and the same weight but a greater surface area than that of solid spheres; direct contact with tissue to release ions for uptake by macrophages without phagocytosis of particles; immunocompetence |
| 06/08/2006 | US20060121041 Gpcs as modifiers of the irrtk p21 pathways and methods of use |
| 06/08/2006 | US20060121035 Methods for treating diabetes |
| 06/08/2006 | US20060121029 Method and composition for regulating the activity of regulatory t cells |
| 06/08/2006 | US20060120973 powders containing human growth hormone; for treatment or prevention of growth retardation, growth hormone deficiency, or for control of HIV-related wasting and cachexia |
| 06/08/2006 | DE20122582U1 Zubereitung für Restenoseprophylaxe Preparation for prophylaxis of restenosis |
| 06/08/2006 | CA2589638A1 7-membered ring compound and method of production and pharmaceutical application thereof |
| 06/08/2006 | CA2588868A1 Remedy for alzheimer's disease |